Effectiveness of the Brazilian Diabetes Prevention Program

Korábbi kezelés

• Continuous use of the following medications:
  • Corticosteroids other than topical, ophthalmic, or inhaled preparations Antineoplastic agents Psychoactive agents Other medications.

Más betegség

• Underlying disease likely to limit life expectancy and/or increase the risk of interventions influencing the risk of developing T2D
• Diagnosis of Renal Disease
• Diagnosis of Pulmonary Disease
• Gastrointestinal Disease
• Secondary prevention for Cardiovascular Disease
• Endocrine Diseases
• Uncontrolled Hypertension
• Diagnosis of Polycystic Ovary Syndrome (self-reported)
• Patients undergoing treatment for Tuberculosis (except those using isoniazid [INH] as prophylaxis)
• Presence of diseases that may severely reduce life expectancy or the ability to participate in the study
• Severe psychiatric disorders that, in the opinion of the clinical team, hinder participation in the program
• Congestive Heart Failure (CHF) with a New York Heart Association Functional Class (NYHA) > 2
• Participant from the pilot Randomized Clinical Trial (Brazilian Diabetes Prevention Program: Pilot Study (PROVEN-Dia), NCT05689658)

Laborértékek

• Diagnosis of Diabetes Mellitus (including current or recent use, within three months, of glucose-lowering medication)

Egyéb

• Weight loss exceeding 10% in the last 6 months (except postpartum-related)
• Pregnant or breastfeeding women
• Acute or chronic excessive alcohol consumption
• Need for referral to a cardiologist according to the Physical Activity Readiness Questionnaire (PAR-Q)
• Current or recent participation (within the last six months) in another clinical trial that impacts the interventions and/or is associated with the study outcomes (in case of doubt, contact the coordinating center)
• Likely relocation away from the research collaborating center within the next 3 years
• Another household member is a participant or a team member of the PROVEN-DIA study
• Unwillingness to accept treatment assignment by randomization and/or refusal to participate in the study (signing the Informed Consent Form)

• Be 18 years or older (no maximum age for being eligible)
• Have a body mass index (BMI) between 18,5 and 34,9kg/m²
• Have, at least, one electronic device (includes any of the following devices):
  • Computer
  • Laptop/notebook
  • Tablet
  • Smartphone
• Have access to internet (broadband, 3G, 4G, 5G, among others) Without previous nutritional counseling (within the 6 months prior to recruitment/randomization/intervention) Without supervision by a Physical Education Professional (Personal Trainer) in the past 6 months
• Living near the research center (at maximum 60 minutes)
• Diagnosis of prediabetes defined as two HbA1c measurements between 5.7% and 6.4% collected 7 to 90 days apart.